Global Genome Editing Market Size & Outlook

(crispr)/cas9 was the largest segment with a revenue share of 43.52% in 2023. Horizon Databook has segmented the Global genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.

Recently developed gene editing tools hold enormous potential in human healthcare management. Specifically, emergence of targeted genome modification that deploys designer nucleases, such as CRISPR and TALEN, have reshaped the investigation of gene function and further development of therapeutics. A broader understanding of genes is achieved using genetically engineered preclinical models.

Success of these tools in development of preclinical models which mimics human physiology and disease genotype & phenotype is expected to enhance the adoption of these technologies in the future market. Usage of these preclinical models is expected to grow in the coming years as they hold considerable potential to ensure higher success of preclinical research.

Biological models developed using gene editing tools are successfully employed to study and treat genetic and rare disease including monogenic recessive disorders that affect hematopoietic systems such as Wiskott -Aldrich syndrome and SCID. Hence, with growth of these preclinical models, this market is expected to witness lucrative growth in revenue generation.